Asthma Clinical Trial
To evaluate current and novel therapies and management strategies for children with asthma. The emphasis is on clinical trials that help identify optimal therapy for children with different asthma phenotypes, genotypes, and ethnic backgrounds and children at different developmental stages.
BACKGROUND:
Asthma is a complex disease that often starts early in life. Exacerbations can be triggered
by a number of agents such as allergens, respiratory infections, environmental tobacco smoke
and pollutants, drugs, chemicals, exercise, cold air, infections and strong emotion making
asthma therapy difficult and sometimes complicated. Multiple medications are often required
to treat symptoms (bronchodilator agents such as beta-2 adrenergic agonists, theophylline,
and anticholinergics), as well the underlying disease process (anti-inflammatory agents such
as inhaled and systemic corticosteroids, cromolyn sodium and nedocromil; and leukotriene
modifiers).
The prevalence of asthma is increasing in all age groups, but most particularly in children
under the age of 18 years. In 1992, the prevalence of self-reported asthma among persons
under 18 years of age was 7.2 percent, compared to 5.1 percent among all persons. The most
rapid increase in asthma has occurred in children under 5 years old, with rates increasing
over 160 percent over the past 15 years. Among all ages, over 450,000 hospitalizations,
5,000 deaths, and more than 100 million days of restricted activity are due to asthma every
year. Yet the burden of asthma disproportionately affects children. For example, asthma
hospitalization rates are highest among persons age 0-4 years, and have increased over 28
percent in the last 15 years; mortality rates increased faster among those aged 5 to-12
years than among those age 15-34 years and neither changes in disease coding nor improved
recognition of asthma fully explain these increases. Nearly one third of children restrict
their activities due to asthma, including participation in physical education and sports.
Despite major advances in understanding the etiology and pathophysiology of asthma and the
development of new therapeutic modalities to control symptoms and prevent exacerbations,
effective therapies are not widely used in the pediatric health care community. Further, the
long term effects and side effects of asthma medications in children, especially children
under the age of 12 years, are not well understood. Much remains to be learned about the
impact of asthma therapy at different ages and at different points in the natural history of
the asthma in altering the progression, chronicity, or severity of the disease.
There is an urgent need to rapidly evaluate new and existing therapeutic approaches for
children with asthma, and to disseminate the findings to health care professionals, patients
and the public. There are several reasons why a pediatric asthma clinical research network
will accelerate clinical research and meet this need. The highly variable and sometimes
complicated clinical manifestations of asthma often make it difficult to accumulate a large
number of comparable patients in one center. Further, uniformity in treatment protocols may
reduce the number of patients needed at each clinical center. Also, the network mechanism
will help pool the necessary clinical expertise and administrative resources to facilitate
the conduct of multiple and novel therapeutic trials in a timely, efficient manner. This, in
turn, would promote rapid dissemination of research findings to health care professionals.
DESIGN NARRATIVE:
Prevention of Early Asthma in Kids (PEAK) began recruitment in January 2001 and evaluated
whether administering inhaled corticosteroids to 24-48 month old children at risk of
developing asthma prevented the development of persistent asthma. All subjects were expected
to be randomized prior to December 2001 with study completion by September 2004. The study
was a double blind, randomized, placebo controlled, parallel comparison of inhaled
fluticasone to placebo. There was a four week run-in period to qualify and characterize
children. A total of 285 children were randomized to one of two treatment groups; one
receiving active treatment, the other placebo. The study was based on a continuous treatment
schedule for a period of twenty-four months, followed by an observation period of one year
during which the main outcomes were assessed. The primary outcome measure was the number of
asthma-free days. Secondary outcomes included number of exacerbations, use of asthma
medications, and lung function. There were three specific objectives of the study: 1) To
assess if chronic therapy with inhaled corticosteroids initiated in children four years or
less at high risk of developing asthma can prevent the development of significant asthma at
four to six years of age, 2) To determine if asthma therapy as described above can prevent
both losses in lung function and the development of bronchial hyperresponsiveness (BHR)
associated with early onset asthma, and 3) To assess potential side effects that may be
associated with long term use of inhaled steroids in early life. PEAK study outcomes were
presented at the 2005 annual meetings of the American Academy of Allergy, Asthma, and
Immunology and the American Thoracic Society. A manuscript has been submitted for
publication by the New England Journal of Medicine.
The study completion date listed in this record was obtained from the "Completed Date"
entered in the Query View Report System (QVR).
;
Intervention Model: Crossover Assignment, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|